systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-168Research ArticleСТАТЬИARTICLESМетаболические и антиоксидантные эффекты небиволола при лечении больных артериальной гипертензиейНапалковД. А.noemail@neicon.ruГоловенкоЕ. Н.noemail@neicon.ruМосковская медицинская академия имени И.М.СеченоваRussian Federation200823122022544042Copyright © Напалков Д.А., Головенко Е.Н., 20222022Напалков Д.А., Головенко Е.Н.Напалков Д.А., Головенко Е.Н.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/168ReferencesSchmidt АС, Graf С, Brixius K, Scholze1 J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study. Clin Drug Investigat 2007; 27 (12): 841-9.Schmidt АС, Graf С, Brixius K, Scholze1 J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study. Clin Drug Investigat 2007; 27 (12): 841-9.Lithel HO. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabet Care 1991; 14: 203-9.Lithel HO. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabet Care 1991; 14: 203-9.Ignarro L, Zanchetti A, Vintila MM, Redon J. Cardiovascular risk management: the role of nebivolol. June 2008 Supplement of Practicing Medicine. Information and Management Journal.Ignarro L, Zanchetti A, Vintila MM, Redon J. Cardiovascular risk management: the role of nebivolol. June 2008 Supplement of Practicing Medicine. Information and Management Journal.Kuroedov A, Cosentino F, Lusher TF. Pharmacological mechanisms of clinically favorable properties of a selective b1-adrenoreceptor antagonist, nibivolol. Cardiovasc Drug Rev 2004; 22 (3): 155-68.Kuroedov A, Cosentino F, Lusher TF. Pharmacological mechanisms of clinically favorable properties of a selective b1-adrenoreceptor antagonist, nibivolol. Cardiovasc Drug Rev 2004; 22 (3): 155-68.Cockeroft JR, Chowienezyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginin/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71.Cockeroft JR, Chowienezyk PJ, Brett SE et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginin/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71.Pessina AC. Metabolic effects and safety profile of nebivolol. J Cardiovasc Pharmacol 2001; 38 (Suppl. 3): 33-5.Pessina AC. Metabolic effects and safety profile of nebivolol. J Cardiovasc Pharmacol 2001; 38 (Suppl. 3): 33-5.Peter P, Martin U, Sharma A et al. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther 2006; 31: 153-9.Peter P, Martin U, Sharma A et al. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther 2006; 31: 153-9.Poirier L, Cleroux J, Nadeau A et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19: 1429-35.Poirier L, Cleroux J, Nadeau A et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19: 1429-35.Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation 2001; 104: 511-4.Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation 2001; 104: 511-4.Pasini AF, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-96.Pasini AF, Garbin U, Nava MC et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-96.Falciani M, Rinaldi B, D'Agostino B et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001; 38: 922-9.Falciani M, Rinaldi B, D'Agostino B et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001; 38: 922-9.Brehm BR, Wolf SC, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49: 430-9.Brehm BR, Wolf SC, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49: 430-9.Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective b-blockers in treatment of hypertension. A meta-analysis. High Blood Press Cardiovasc Prev 2005; 12 (1): 27-35.Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective b-blockers in treatment of hypertension. A meta-analysis. High Blood Press Cardiovasc Prev 2005; 12 (1): 27-35.Predel HG, Mainka W, Schillings W et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens 2001; 15 (10): 715-21.Predel HG, Mainka W, Schillings W et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens 2001; 15 (10): 715-21.Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215-25.Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215-25.SENIORS, data on file. In: The Proceedings of the World Congress of Cardiology; 2006 Sept. 2-6, Barcelona.SENIORS, data on file. In: The Proceedings of the World Congress of Cardiology; 2006 Sept. 2-6, Barcelona.Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24 (3): 591-6.Celik T, Iyisoy A, Kursaklioglu H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24 (3): 591-6.Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a b-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67 (8): 1097-107.Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a b-adrenoceptor antagonist with unique characteristics. Drugs 2007; 67 (8): 1097-107.Дедов И.И., Бондаренко И.З., Соляник Ю.А. и др. Метаболические эффекты небиволола у больных сахарным диабетом 2 типа. Кардиология. 2001; 5 (41): 35-7.Дедов И.И., Бондаренко И.З., Соляник Ю.А. и др. Метаболические эффекты небиволола у больных сахарным диабетом 2 типа. Кардиология. 2001; 5 (41): 35-7.Fogari R, Zoppi A, Lazzari P et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753-7.Fogari R, Zoppi A, Lazzari P et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753-7.Маколкин В.И., Ахмедова О.О., Бувальцев В.И. и др. Клинические и метаболические эффекты кардиоселективных b-адреноблокаторов небиволола и метопролола у пациентов с гипертонией и ишемической болезнью сердца в сочетании с сахарным диабетом 2 типа. Кардиология. 2003; 43 (2): 40-3.Маколкин В.И., Ахмедова О.О., Бувальцев В.И. и др. Клинические и метаболические эффекты кардиоселективных b-адреноблокаторов небиволола и метопролола у пациентов с гипертонией и ишемической болезнью сердца в сочетании с сахарным диабетом 2 типа. Кардиология. 2003; 43 (2): 40-3.Rizos E, Bairaktari E, Kostoula A et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8 (2): 127-34.Rizos E, Bairaktari E, Kostoula A et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8 (2): 127-34.Lacourciere Y, Poirier L, Lefebvre J et al. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32 (7): 660-6.Lacourciere Y, Poirier L, Lefebvre J et al. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32 (7): 660-6.Lacourciere Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 1994; 8 (4): 283-8.Lacourciere Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 1994; 8 (4): 283-8.Kaiser T, Heise T, Nosek L et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006; 24: 1397-403.Kaiser T, Heise T, Nosek L et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006; 24: 1397-403.
The authors declare that there are no conflicts of interest present.